Clinical Trial Update: Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates a first-line study of Glecirasib plus Ivonescimab for KRAS G12C-mutated non-small cell lung cancer, currently in Phase 1/2 and n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Glecirasib
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: NSCLC Stage IV, KRAS G12C | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING